Drug products: Emovat®
ATC code: D07AB01
Substances: clobetasone, clobetasone butyrate
Published controlled studies on differences between men and women regarding efficacy and safety of clobetasone are lacking.
The present evidence concerning differences between men and women is very limited and do not motivate differentiation in dosing or treatment.
Topical corticosteroids may be systematically absorbed if used on large areas, on broken skin, or under occlusive dressings . No difference between men and women has been shown for transdermal absorption in general .
No studies with a clinically relevant sex-analysis regarding the effects of clobetasone have been found.
No studies with a clinically relevant sex-analysis regarding adverse effects of clobetasone have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men .
Date of litterature search: 2017-02-02
Reviewed by: Mia von Euler
Approved by: Linnéa Karlsson Lind